Neos Therapeutics Files For A $69 Million IPO

Neos Therapeutics, a late stage biotechnology firm developing formulations of approved therapies for attention deficit hyperactivity disorder (ADHD), filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $69 million in an initial public offering (IPO). The company was founded in 1994 and booked $1 million in sales for the 12 months ended March 31, 2015. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets were the joint bookrunners on the deal. No pricing terms were disclosed.

This was reported by Renaissance Capital on June 19, 2015.

Contact Information: Neos Therapeutics, Inc., 2940 N. Hwy . . .